IBS Subtypes: IBS-D, IBS-C, IBS-M & IBS-U — Rome IV Criteria & Treatment Guide

Irritable bowel syndrome is not one disease. It is a family of gut-brain disorders sharing a diagnostic framework but differing fundamentally in their underlying biology, their symptom patterns, and — critically — their treatment. Treating IBS-D the same as IBS-C is a clinical mistake that delays relief and wastes months of trial-and-error. This guide decodes the Rome IV criteria, explains the Bristol Stool Scale subtyping system, and walks through the distinct pathophysiology and evidence-based treatment pathways for each subtype.

Rome IV Diagnostic Criteria (2016)

The Rome IV criteria, updated in 2016, provide the current diagnostic standard for IBS. The framework was designed to move away from symptom exclusion (ruling out every other condition) toward positive diagnosis based on specific clinical features.

For a diagnosis of IBS, a patient must have recurrent abdominal pain at least 1 day per week in the last 3 months, associated with two or more of the following:

• Related to defecation — pain improves or worsens with bowel movements
• Associated with a change in stool frequency — more or fewer bowel movements than baseline
• Associated with a change in stool form (appearance) — classified by the Bristol Stool Scale

Symptoms must have started at least 6 months before diagnosis. This distinguishes IBS from acute self-limiting gut disturbances.

Bristol Stool Scale — The Subtyping Ruler

IBS subtyping is based entirely on the Bristol Stool Form Scale (BSFS), a validated 7-point classification of stool consistency — not stool frequency. The scale runs from type 1 (separate hard lumps) through type 7 (entirely liquid). Types 3-4 are considered normal; types 1-2 indicate slow transit; types 6-7 indicate accelerated transit.

For classification, only stools on days with abnormal bowel habits are counted. This is a critical nuance: a patient having three normal stools for every one loose stool may still classify as IBS-D depending on which stools are abnormal.

The Four IBS Subtypes — Classification Criteria

Pathophysiology — Why Each Subtype Is Different

IBS-D: The Accelerated, Hypersensitive Gut

IBS-D is characterized by fundamentally accelerated gastrointestinal transit. The driving mechanisms are more complex than simply "moving too fast." Enterochromaffin cells — the gut's primary serotonin producers — are overactive in IBS-D, releasing excess 5-hydroxytryptamine (5-HT). Elevated serotonin accelerates peristalsis and sensitizes afferent nerves, producing both urgency and visceral pain at stool volumes that wouldn't trigger discomfort in a healthy gut.

Increased gut permeability is a consistent finding in IBS-D. Tight junction proteins between intestinal epithelial cells are disrupted, allowing luminal antigens, bacteria, and toxins to access the lamina propria. This triggers mast cell activation, local immune responses, and sensitization of submucosal nerve fibers — a mechanism that perpetuates both the diarrhea and the pain independently of what triggers it.

Post-Infectious IBS (PI-IBS)

One of the best-characterized subtypes of IBS-D is post-infectious IBS. Up to 30% of people who survive acute gastroenteritis go on to develop persistent IBS — almost always the diarrhea-predominant subtype. Campylobacter jejuni is the strongest predictor among bacterial pathogens; Salmonella, Shigella, and norovirus also carry significant risk.

The mechanism involves acute gut injury leading to increased permeability, altered microbiome composition, immune activation, and lasting enteric nervous system sensitization. Anti-CdtB and anti-vinculin antibodies — triggered by molecular mimicry during bacterial infection — have been identified as potential biomarkers of PI-IBS and may partially explain the immune-driven nature of the condition.

Bile Acid Malabsorption (BAM) — The Overlooked IBS-D Mimicker

An estimated 25-30% of IBS-D patients have bile acid malabsorption (BAM) as a primary or contributing driver — yet it is vastly underdiagnosed because standard IBS workup rarely tests for it. When bile acids are not adequately reabsorbed in the terminal ileum, they enter the colon and act as potent secretagogues and motility stimulants, causing secretory diarrhea that mirrors IBS-D.

Diagnosis requires a SeHCAT (selenium homocholic acid taurine) scan — the gold standard in countries where it's available — or fecal bile acid testing. Treatment with a bile acid sequestrant such as cholestyramine can dramatically improve symptoms in BAM-positive patients. If you have IBS-D that hasn't responded to standard interventions, BAM is worth investigating.

IBS-C: Slow Transit, Silent Nerves, Secretion Failure

IBS-C represents the opposite end of the transit spectrum. Colonic transit is delayed, and the mechanisms involved point to a different biological profile. Where IBS-D involves excess serotonin, IBS-C is associated with relative serotonin deficiency — reduced postprandial 5-HT release leads to sluggish peristalsis and less fluid secretion into the lumen.

Chloride channel dysfunction is a key driver. Reduced CFTR and ClC-2 chloride channel activity in the intestinal epithelium means less fluid is secreted into the gut lumen, producing drier, harder stools that transit more slowly. This is the rationale for the pharmacological treatments that specifically target these channels.

Visceral hypersensitivity in IBS-C is present but operates differently from IBS-D. Patients with IBS-C often have higher visceral pain thresholds than IBS-D patients in experimental balloon distension studies — yet they still experience significant abdominal pain. This likely reflects different central sensitization patterns and altered gut-brain axis signaling rather than simple nerve sensitization. Common dietary triggers include dairy, gluten-containing foods, high-fat meals, and high-FODMAP foods that significantly delay gastric emptying.

IBS-M: The Alternating Challenge

IBS-M — mixed subtype — is arguably the most difficult to manage because patients alternate between constipation and diarrhea phases, often unpredictably. The pathophysiology reflects this duality: IBS-M patients show elements of both accelerated and delayed transit at different times, with stress and high-FODMAP foods acting as the dominant triggers for phase shifts.

Clinically, this creates a trap: treating the diarrhea phase aggressively can precipitate a constipation phase, and vice versa. The low-FODMAP diet is particularly important in IBS-M because it addresses the fermentation-driven gas and bloating that often accompanies both phases, without being directionally biased.

Evidence-Based Treatment by Subtype

IBS-D Treatment Protocol

Rifaximin (Xifaxan 550mg TID ×14 days) is the only gut-selective antibiotic approved for IBS without constipation in adults. As a non-absorbable antibiotic that stays within the gut lumen, rifaximin reshapes the small intestinal microbiome without systemic side effects. The TARGET 1 and TARGET 2 trials demonstrated approximately a 40% responder rate (defined as adequate relief of both global IBS symptoms and bloating), significantly outperforming placebo. Importantly, it can be repeated with similar efficacy — IBS-D is not cured by rifaximin, but symptoms can be reset.

Alosetron (Lotronex), a 5-HT3 antagonist, slows gut transit and reduces visceral hypersensitivity. It is restricted to women with severe diarrhea-predominant IBS who have failed conventional therapy, due to rare but serious risks of ischemic colitis and severe constipation. It operates through a Restricted Program in Medicines Strategy (REMS) and requires prescriber enrollment.

Loperamide (over-the-counter) provides symptomatic relief by reducing motility and increasing sphincter tone. It does not address the underlying pathophysiology and is recommended for breakthrough management rather than daily use. Peppermint oil (enteric-coated) works via calcium channel blockade in smooth muscle, relaxing intestinal musculature and reducing urgency and cramping.

IBS-C Treatment Protocol

Linaclotide (Linzess) is a guanylate cyclase-C (GC-C) receptor agonist that works through a dual mechanism: it increases intestinal fluid secretion by activating CFTR chloride channels, and it reduces visceral pain by blocking pain-signaling afferents in the gut — independently of its laxative effect. The RELIEF and CLARITY trials demonstrated superior improvement in both stool frequency and abdominal pain versus placebo. This pain-reducing mechanism distinguishes linaclotide from simple laxatives.

Plecanatide (Trulance) works through the same GC-C pathway as linaclotide but activates in a pH-dependent manner, activating more in the proximal gut where pH is lower. Clinical evidence shows similar efficacy to linaclotide.

Lubiprostone (Amitiza) activates ClC-2 chloride channels in intestinal epithelial cells, increasing luminal fluid and accelerating transit without the systemic hormonal effects of older prokinetics. It is FDA-approved for IBS-C in women (evidence in men is limited).

Tegaserod (Zelnorm), a 5-HT4 agonist that accelerates transit, was withdrawn then returned to limited use for IBS-C in women under 65 without cardiovascular risk factors. Its utility is constrained by cardiac safety concerns.

Dietary Interventions — Applicable to All Subtypes

The low-FODMAP diet remains the most evidence-based dietary intervention for IBS across all subtypes, with 50-80% symptom response rates in clinical studies. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are short-chain carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by colonic bacteria, producing gas and osmotic water retention. The protocol involves a strict elimination phase (4-6 weeks), followed by systematic reintroduction to identify individual triggers.

Soluble fiber (psyllium husk) has evidence in both IBS-D and IBS-C — it adds bulk without rapid fermentation, moderating transit in either direction. Insoluble fiber (wheat bran) worsens IBS symptoms and should be avoided.

Gut-Brain Axis Interventions

Psychological comorbidity in IBS is not incidental. Anxiety affects 40-60% of IBS patients and depression affects approximately 30%, reflecting the bidirectional gut-brain axis — a dysregulated enteric nervous system influences mood, and psychological distress directly alters gut motility and sensitivity through the autonomic nervous system. Treating only the gut without addressing the brain is incomplete management.

Cognitive behavioral therapy (CBT) with gut-specific focus shows RCT evidence for IBS symptom reduction. Gut-directed hypnotherapy (GDH), developed at Manchester by Peter Whorwell, has over three decades of evidence demonstrating significant reductions in IBS symptom severity and quality of life improvements that last beyond the treatment period. SIBO (small intestinal bacterial overgrowth) deserves mention — studies report 20-84% prevalence in IBS depending on whether lactulose or glucose breath testing is used, with the wide range reflecting the controversy around lactulose as a substrate (which may produce false positives from accelerated transit in IBS-D).

Ruling Out Mimics — Key Investigations

Rome IV criteria do not require extensive investigation in the absence of alarm features. However, several targeted tests improve diagnostic confidence and identify treatable conditions that mimic IBS:

• Fecal calprotectin — elevated in IBD (Crohn's disease, ulcerative colitis), normal in IBS. A cost-effective screen to avoid unnecessary colonoscopy in younger patients without alarm features.
• SeHCAT scan or fecal bile acid testing — for IBS-D patients not responding to standard therapy. Identifies bile acid malabsorption (BAM) in 25-30% of IBS-D cases.
• Anti-CdtB and anti-vinculin antibodies — emerging biomarkers for post-infectious IBS. Not yet standard of care but commercially available and can support diagnosis in patients with clear PI-IBS history.
• Celiac serology (tTG-IgA) — celiac disease mimics IBS-D; screen once, especially in patients with northern European ancestry.
• Colonoscopy — indicated only with alarm features. Not recommended as routine IBS workup in patients under 50 without red flags.
• Thyroid function (TSH) — hypothyroidism can cause IBS-C-like symptoms; hyperthyroidism can mimic IBS-D.

More From GutCode